PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 14, 2026Open Forum Infectious Diseases0 citationsOpen Access

P-2141. Candidemia after Solid Organ Transplantation

View Full Paper
SKSafah KhanLHLana HasanJLJ. Lum

Key Points

  • Characterize the epidemiology and outcomes of candidemia in solid organ transplant recipients.
  • Retrospective cohort study of adult SOT recipients diagnosed with candidemia from 2009 to 2024.
  • Epidemiological characteristics and mortality factors assessed within 30 days of diagnosis.
  • Survival analysis using Kaplan-Meier curves to evaluate mortality influences.
  • Included 88 SOT recipients with C. glabrata the most commonly isolated species.
  • Median time to candidemia was 200 days post-transplant; 36.4% occurred within 30 days.
  • Initial antifungal therapy was primarily micafungin (89.2%); mortality was 42% within 30 days.

Abstract

Abstract Background Invasive fungal infections, most commonly due to Candida, are a dreaded complication after solid organ transplantation (SOT). This study aims to characterize the epidemiology of candidemia in SOT recipients at a tertiary transplant center.Table 1:Baseline characteristics of participants.Figure 1:Distribution of Candida Species.Figure 1 represents the distribution of candida species isolated in the study cases. Methods A retrospective cohort study was conducted on adult SOT recipients diagnosed with candidemia between 1/1/2009 and 3/31/2024. Epidemiological characteristics were described and stratified by mortality within 30 days of diagnosis. Secondary outcomes included ocular candidiasis and post-transplant Candida recurrence. Survival analysis was performed to investigate the factors associated with mortality and depicted using Kaplan-Meier curves.Figure 2:Factors Influencing Mortality in SOT Recipients with Candidemia.Figure 2 depicts Kaplan Meier curves for potential factors influencing mortality in SOT Recipients with Candidemia (a) Time from Transplant, (b) Nosocomial Onset, (c) Shock, (d) Source Control. Results We included 88 SOT recipients, including 11 heart, 10 intestinal/multivisceral, 14 kidney, 16 liver, 20 lung, 1 vascular allograft, 16 multiple-organ recipients. Epidemiologic characteristics are summarized in table 1. Median time to candidemia was 200 days post-transplant, with 36.4% occurring within the first 30 days. C. glabrata was most isolated (40%), followed by C. albicans (25%), and C. parapsilosis (12.5%; figure 1). Coinfection with two distinct candida species was also observed in 4 cases. Primary sources of infection were central line-associated bloodstream infection (CLABSI, 36.4%) and intra-abdominal sources (31.8%). Initial antifungal therapy was predominantly with micafungin (89.2%). Source control was obtained in most cases (85.2%). Most patients developed septic shock (58.0%), required intubation (51.1%), and ICU admission (78.4%). Two (3.6%) of 55 patients who underwent formal eye examination had signs of ocular candidiasis. 37 (42.0%) died within 30 days of diagnosis. Shock and lack of source control were associated with increased mortality, while time after SOT and nosocomial onset of candidemia were not (figure 2). Conclusion Candidemia is a devastating complication following SOT. Despite aggressive antifungal therapy and source control, mortality is high. Severity of initial presentation and source control seem more predictive of survival rather than baseline characteristics. These findings emphasize the need for improved prophylaxis and treatments to improve outcomes in this vulnerable population. Disclosures All Authors: No reported disclosures

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Khan et al. (2026) studied this question.

synapsesocial.com/papers/6966e71813bf7a6f02bff554https://doi.org/10.1093/ofid/ofaf695.2304
Ask AI
Helpful
Bookmark
Share
View Full Paper